“We made significant strides in 2024 and the first quarter of 2025 to complete our Phase 2b studies of EFX and advance our Phase 3 SYNCHRONY program. The preliminary topline results from our Phase 2b SYMMETRY study, which we reported last month, showed an unprecedented, statistically significant reversal of compensated cirrhosis due to MASH in patients treated with 50mg EFX for 96 weeks,” said Andrew Cheng, M.D., Ph.D., president and chief executive officer of Akero. “These exciting results, which build on last year’s week 96 results for the Phase 2b HARMONY study in patients with pre-cirrhotic MASH, show EFX’s potential to improve outcomes not only for patients with pre-cirrhotic fibrosis, but also for those with compensated cirrhosis-a population in urgent need of effective therapeutic options. We remain committed to advancing EFX as a potential therapeutic breakthrough for individuals living with advanced MASH and look forward to building upon this momentum as we progress our Phase 3 SYNCHRONY program.”
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AKRO:
- 89bio initiated with an Outperform at Wolfe Research
- 89bio price target raised to $38 from $25 at UBS, says shares ‘undervalued’
- Akero Therapeutics price target raised to $109 from $42 at UBS
- Biotech Alert: Searches spiking for these stocks today
- Akero upgraded to Buy at BofA after ‘transformative’ liver data
Questions or Comments about the article? Write to editor@tipranks.com